FindTrial
Sign In

Diagnosis and risk assessment of thyroid nodule by multimodal diagnosis system

Diagnosis and risk assessment of thyroid nodule by multimodal diagnosis system

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100041694
Enrollment
Unknown
Registered
2021-01-01
Start date
2021-01-01
Completion date
Unknown
Last updated
2021-03-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thyroid nodules

Interventions

Gold Standard:Surgical resection or Bethesda category II or VI.
Index test:Basic&#32
information
&#32
Conventional&#32
ultrasound&#32
examination
Contrast-enhanced&#32
Thyroid&#32
fine&#32
needle&#32
aspiration&#32
biopsy&#32
and&#32
gene&#32
(BRAF&#32

Sponsors

Lanzhou University Second Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1) Thyroid nodules undergo both conventional ultrasound and contrast-enhanced ultrasound examination; 2) Confirmed by surgical pathology or thyroid fine needle aspiration cytology pathology (FNA); 3) Suspected malignant thyroid nodules tested for BRAF V600E, TERTp, and RAS mutations.

Exclusion criteria

Exclusion criteria: 1) Allergic to contrast agents; 2) Completely calcified nodules; 3) Nodules confirmed by ultrasound and pathology are inconsistent.

Design outcomes

Primary

MeasureTime frame
benignity and malignancy;risk assessment;SEN, SPE, ACC, AUC of ROC;—

Countries

China

Contacts

Public ContactFang Nie

Lanzhou University Second Hospital

ery_nief@163.com+86 931-8942525

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026